Log In
Print
BCIQ
Print
Print this Print this
 

HyQvia

Also known as: formerly HyQ

  Manage Alerts
Collapse Summary General Information
Company Baxter International Inc.
DescriptionSubcutaneous formulation of IV Gammagard, an IgG antibodies plasma-based therapy, and rHuPH20, a recombinant human PH20 hyaluronidase enzyme
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentApproved
Standard IndicationImmunodeficiency
Indication DetailsTreat primary immunodeficiency disorder (PID); Treat primary immunodeficiency disorders and myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections
Regulatory Designation

Partner

Halozyme Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today